NVDA
NVIDIA
-- 115.430 TSLA
Tesla
-- 225.310 INTC
Intel
-- 25.920 PLTR
Palantir
-- 83.890 GOOG
Alphabet-C
-- 162.670 
NEWS
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Tuesday, 10th December at 7:00 am
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—
—Favorable safety and tolerability results with no new safety signal identified—
—Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial—
—Trial participants continue to receive neflamapimod during open-label extension—
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) ("CervoMed" or the "Company"), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) or any of its key secondary endpoints – change from baseline in Timed Up and Go (TUG) test, change from baseline in a Neuropsychological Test Battery (NTD) and the Clinician's Global Impression of Change (CGIC). Initial analysis shows that target plasma drug concentrations were not achieved during the double-blind phase of the trial, which may have adversely impacted trial results.
Tuesday, 10th December at 7:00 am
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—
—Favorable safety and tolerability results with no new safety signal identified—
—Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial—
—Trial participants continue to receive neflamapimod during open-label extension—
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) ("CervoMed" or the "Company"), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) or any of its key secondary endpoints – change from baseline in Timed Up and Go (TUG) test, change from baseline in a Neuropsychological Test Battery (NTD) and the Clinician's Global Impression of Change (CGIC). Initial analysis shows that target plasma drug concentrations were not achieved during the double-blind phase of the trial, which may have adversely impacted trial results.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit : Grrrrr